首页 > 市场调查报告书 > 医疗设备

妇科治疗

市场调查报告书

商品编码

1777649

全球子宫肌瘤治疗药物市场

Uterine Fibroid Treatment Drugs

出版日期: 2025年07月28日 | 出版商:

Global Industry Analysts, Inc. | 英文 376 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球子宫肌瘤药物市场规模将达到 36 亿美元

2024年全球子宫肌瘤药物市场规模估计为21亿美元，预计在分析期内（2024-2030年）将以9.0%的复合年增长率增长，到2030年将达到36亿美元。本报告分析的细分市场之一—促性腺激素分泌释放激素促效剂，预计其复合年增长率将达到10.4%，到分析期末达到14亿美元。促性腺激素分泌释放激素拮抗剂细分市场在分析期间内的复合年增长率估计为6.8%。

美国市场规模估计为 5.777 亿美元，中国市场预计复合年增长率为 14.2%

美国子宫肌瘤药物市场规模预计在2024年达到5.777亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到7.893亿美元，在2024-2030年的分析期间内，复合年增长率为14.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为4.5%和8.6%。在欧洲，预计德国市场的复合年增长率约为6.1%。

全球子宫肌瘤药物市场－主要趋势与驱动因素摘要

子宫肌瘤盛行率的不断上升是否会改变药物治疗的需求？

子宫肌瘤（平滑肌瘤）是育龄妇女最常见的良性肿瘤之一，全球盛行率估计接近 20% 至 40%。随着人们认识的提高、诊断的改进以及医疗保健可及性的改善，寻求治疗子宫肌瘤相关症状（包括月经过多、骨盆疼痛、不孕症和贫血）的妇女数量显着增加。由于许多患者寻求子宫切除术和肌瘤摘除等侵入性手术的治疗方法，药物治疗正逐渐流行起来。患者偏好的这种转变显着扩大了对肌瘤药物作为第一线或术前治疗选择的需求。子宫肌瘤最常影响 30 多岁和 40 多岁的女性，其中许多人仍处于生育年龄。因此，保持生育能力和避免漫长的恢復期是核心关注点，这进一步推动了对有效的非手术治疗方法的需求。种族差异，尤其是非裔女性较高的发生率和严重程度，也导致了医疗资源匮乏和高风险族群中子宫肌瘤的发生率上升。这些人口统计和临床趋势为子宫肌瘤药物治疗领域的持续发展奠定了坚实的基础。

新型药物和荷尔蒙如何推动治疗方案的进步？

药物创新正在迅速改变子宫肌瘤治疗的格局，新型改良药物能够更好地控制症状、减少副作用并提高治疗便利性。促性腺激素分泌释放激素 (GnRH) 类似物长期以来一直用于缩小子宫肌瘤并控制大量出血，但由于骨质流失和潮热等低雌激素副作用，其长期使用受到限制。这为提供更有针对性的荷尔蒙控制且安全性更高的新治疗方法铺平了道路，例如选择性孕激素受体调变器(SPRM) 和口服 GnRH 拮抗剂。利高利 (rilgolix) 等药物通常与雌二醇或炔诺酮联合使用，如今正成为有效的口服疗法，兼具疗效和患者耐受性。这些新型药物能够长期控制症状，并且越来越多地被用作手术干预的替代或辅助手段。同时，缓释性和联合治疗等药物传递机制的进步正在提高患者的依从性，并扩大个人化治疗方案。子宫肌瘤治疗的药物研发管线比以往任何时候都更加活跃，目前正在进行的临床试验正在探索新的荷尔蒙调节、抗纤维化甚至免疫调节疗法。这些创新不仅改善了治疗效果，也强化了市场向个人化、非侵入性子宫肌瘤治疗的转变。

病患偏好和医疗模式的改变是否推动了非手术治疗的采用？

全球对以患者为中心的微创治疗的重视正在从根本上改变子宫肌瘤的治疗方式。越来越多的女性正在寻求治疗方法方法。这使得药物治疗成为一种颇具吸引力的选择，尤其对于症状轻微至中度的患者以及等待手术的患者而言。此外，不断发展的门诊护理模式和远端医疗平台的扩展促进了远距离诊断、追踪和肌瘤药物的处方，使资源匮乏的地区更容易获得治疗。直销健康平台和数位健康品牌也在揭开月经健康和子宫肌瘤的神秘面纱，鼓励更多女性儘早寻求治疗方面发挥作用。此外，将药物治疗与其他非侵入性手术（例如子宫动脉栓塞术 (UAE) 和聚焦超音波手术 (FUS)）相结合，为患者和医疗保健提供者在治疗计划方面提供了更大的灵活性。为此，製药公司越来越注重教育、病患支持计画和社区推广，以提高依从性并改善治疗效果。这种以患者主导的势头正在促进更加多样化和包容性的市场环境，在这种环境中，药物既可以作为独立的解决方案，也可以作为更广泛的多治疗策略的组成部分。

哪些因素将推动子宫肌瘤药物市场的长期成长？

子宫肌瘤治疗市场的成长受到临床需求、技术进步、患者人口结构变化和医疗保健服务体係不断发展的共同驱动。一个关键驱动因素是全球子宫肌瘤盛行率的上升，尤其是在 30 至 50 岁的女性中，她们非常积极主动地寻求治疗并保持生殖健康。标靶荷尔蒙疗法的不断扩大，包括 SPRM 和口服 GnRH 拮抗剂，为长期管理提供了更安全、更便捷的选择，引起了患者和医疗保健提供者的浓厚兴趣。此外，世界各地的医疗保健系统正在转向非手术治疗慢性病，为药物治疗子宫肌瘤创造了有利环境。此外，不断加强的宣传宣传活动和妇女健康倡导工作正在改善教育并减少围绕月经健康的耻辱感，从而实现早期诊断并增加对药物治疗解决方案的需求。美国、欧洲和日本等主要市场的报销核准和监管认可也提升了产品的可及性和商业性可行性。大型製药公司和生技企业的投资正在推动研发，而数位健康平台则促进了更广泛的分销和病患参与。这些因素共同推动了子宫肌瘤治疗市场的持续成长，而这得益于技术创新、可及性和日益壮大的全球患者群体。

部分

依药物类别（促性腺激素分泌释放激素促效剂、促性腺激素分泌释放激素拮抗剂、孕激素释放子宫内避孕器/避孕药、非荷尔蒙药物等）、按类型（浆膜下子宫肌瘤、浆膜内子宫肌瘤、黏膜下子宫肌瘤、带蒂子宫肌瘤）和最终用户（医院药房、零售药房等）

受访公司范例

AbbVie Inc.
Abbott Healthcare Pvt. Ltd.
Amring Pharmaceuticals Inc.
AstraZeneca
Bayer AG
Biocon Biologics
Bristol-Myers Squibb Company
Ferring Pharmaceuticals
Gedeon Richter plc
GlaxoSmithKline plc
Hologic, Inc.
Hoffmann-La Roche Ltd
Ipsen Pharma
Kissei Pharmaceutical Co., Ltd.
Medtronic
Merot Medical Systems
Minerva Surgical, Inc.
Myovant Sciences GmbH
Novartis AG
ObsEva

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口情况（成品和原始OEM）预测其竞争地位的变化。这种复杂多变的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

The global market for Uterine Fibroid Treatment Drugs estimated at US$2.1 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Gonadotropin-releasing Hormone Agonists, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Gonadotropin-releasing Hormone Antagonists segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$577.7 Million While China is Forecast to Grow at 14.2% CAGR

The Uterine Fibroid Treatment Drugs market in the U.S. is estimated at US$577.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$789.3 Million by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Uterine Fibroid Treatment Drugs Market - Key Trends & Drivers Summarized

Is the Rising Prevalence of Uterine Fibroids Reshaping the Demand for Drug-Based Therapies?

Uterine fibroids, or leiomyomas, are one of the most common benign tumors in women of reproductive age, with an estimated global prevalence affecting nearly 20% to 40% of women. The rising awareness, improved diagnosis, and increased healthcare access have significantly boosted the number of women seeking treatment for fibroid-related symptoms such as heavy menstrual bleeding, pelvic pain, infertility, and anemia. As many patients look for alternatives to invasive surgical procedures such as hysterectomy and myomectomy, pharmaceutical interventions are gaining renewed traction. This shift in patient preference has significantly expanded the demand for uterine fibroid treatment drugs as first-line or pre-surgical management options. With fibroids more commonly affecting women in their 30s and 40s-many of whom are still in their childbearing years-preserving fertility and avoiding long recovery times has become a central concern, further propelling the need for effective, non-surgical therapies. Ethnic disparities particularly higher incidence and severity among women of African descent are also contributing to a growing patient pool in underserved and high-risk communities. These demographic and clinical dynamics are creating a robust foundation for sustained growth in the drug-based treatment segment for uterine fibroids.

How Are Novel Drug Classes and Hormonal Agents Advancing Therapeutic Options?

Pharmaceutical innovation is rapidly transforming the landscape of uterine fibroid treatment, with new and improved drugs offering enhanced symptom control, fewer side effects, and greater convenience. Gonadotropin-releasing hormone (GnRH) analogs have long been used to reduce fibroid size and manage heavy bleeding, but their association with hypoestrogenic side effects like bone loss and hot flashes has limited long-term use. This has paved the way for newer therapies such as selective progesterone receptor modulators (SPRMs) and oral GnRH antagonists, which offer more targeted hormonal modulation with improved safety profiles. Drugs like relugolix, often used in combination with estradiol and norethindrone, are now emerging as effective oral therapies that balance efficacy with patient tolerability. These novel agents are enabling long-term symptom management and are increasingly being prescribed as alternatives or adjuncts to surgical intervention. In parallel, advancements in drug delivery mechanisms-such as extended-release formulations and combination therapies-are enhancing patient adherence and expanding options for individualized care. With ongoing clinical trials exploring new hormone regulators, anti-fibrotic agents, and even immune-modulating therapies, the pharmaceutical pipeline for uterine fibroid treatment is more dynamic than ever. These innovations are not only improving therapeutic outcomes but are also reinforcing the market’s shift toward personalized, non-invasive fibroid management.

Are Shifting Patient Preferences and Healthcare Models Driving Non-Surgical Treatment Adoption?

The growing global emphasis on patient-centered, minimally invasive care is fundamentally changing how uterine fibroids are managed-putting greater focus on drug-based interventions. Increasingly, women are demanding treatment options that allow them to preserve their uterus, maintain fertility, and avoid extended downtime associated with surgery. This has made pharmacological therapies an attractive choice, particularly for those with mild to moderate symptoms or those awaiting surgery. Moreover, the evolution of outpatient care models and the expansion of telemedicine platforms are facilitating remote diagnosis, follow-up, and prescription of fibroid treatment drugs, making therapies more accessible even in lower-resource settings. Direct-to-consumer health platforms and digital wellness brands are also playing a role in demystifying menstrual health and fibroid awareness, encouraging more women to pursue medical treatment earlier. Furthermore, the ability to combine drug therapy with other non-invasive procedures, such as uterine artery embolization (UAE) or focused ultrasound surgery (FUS), is giving patients and providers more flexibility in treatment planning. In response, pharmaceutical companies are increasingly focusing on education, patient support programs, and community outreach to encourage adherence and improve outcomes. This patient-driven momentum is contributing to a more diversified and inclusive market landscape, where drug therapies serve as both standalone solutions and components of broader multimodal treatment strategies.

What Factors Are Driving Long-Term Growth in the Uterine Fibroid Treatment Drugs Market?

The growth in the uterine fibroid treatment drugs market is driven by a combination of clinical need, technological progress, changing patient demographics, and evolving healthcare delivery systems. A key driver is the increasing global prevalence of fibroids, particularly among women aged 30 to 50, a demographic that is highly active in seeking care and maintaining reproductive health. The expanding pipeline of targeted hormonal therapies, including SPRMs and oral GnRH antagonists, is providing safer, more convenient options for long-term management, thus drawing greater interest from both patients and providers. Healthcare systems around the world are also shifting toward non-surgical management of chronic conditions, creating a favorable environment for the adoption of drug-based fibroid therapies. Additionally, growing awareness campaigns and women's health advocacy efforts are improving education and reducing stigma around menstrual health, leading to earlier diagnosis and greater demand for pharmacologic solutions. Reimbursement approvals and regulatory endorsements in key markets like the U.S., Europe, and Japan are also bolstering product accessibility and commercial viability. Investment from major pharmaceutical companies and biotech startups alike is fueling research and development, while digital health platforms are enabling broader distribution and patient engagement. Together, these factors are ensuring that the uterine fibroid treatment drugs market continues to grow, driven by innovation, accessibility, and an increasingly empowered global patient population.

SCOPE OF STUDY:

The report analyzes the Uterine Fibroid Treatment Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications, Others); Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); End-User (Hospital Pharmacies, Retail Pharmacies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AbbVie Inc.
Abbott Healthcare Pvt. Ltd.
Amring Pharmaceuticals Inc.
AstraZeneca
Bayer AG
Biocon Biologics
Bristol-Myers Squibb Company
Ferring Pharmaceuticals
Gedeon Richter plc
GlaxoSmithKline plc
Hologic, Inc.
Hoffmann-La Roche Ltd
Ipsen Pharma
Kissei Pharmaceutical Co., Ltd.
Medtronic
Merot Medical Systems
Minerva Surgical, Inc.
Myovant Sciences GmbH
Novartis AG
ObsEva

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Uterine Fibroid Treatment Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Global Prevalence of Uterine Fibroids Spurs Sustained Demand for Drug-Based Treatment Alternatives
- Increased Preference for Fertility-Preserving and Non-Surgical Therapies Strengthens Business Case for Pharmacologic Options
- Advancements in Hormonal Drug Classes and Targeted Therapies Propel Innovation in Symptom Management
- Growing Patient Awareness and Early Diagnosis Trends Expand the Addressable Market for Medical Treatment
- Shift Toward Personalized Medicine and Symptom-Specific Formulations Drives Adoption Among Reproductive-Age Women
- Postponement of Childbearing and Changing Reproductive Health Trends Fuel Demand for Uterus-Conserving Therapies
- Regulatory Approvals and Market Entry of Oral GnRH Antagonists Create New Competitive Opportunities
- Expansion of Telehealth and Direct-to-Consumer Gynecology Services Accelerates Access to Treatment Options
- Rising Investments in Women's Health Research and Drug Development Strengthen the Therapeutic Pipeline
- Increased Emphasis on Quality of Life and Menstrual Health Throws Spotlight on Long-Term Medical Management Solutions
- Combination Therapy Approaches Generate Opportunities for Multifaceted and Extended Treatment Plans
- Digital Education Campaigns and Advocacy Efforts Drive Patient Engagement and Reduce Stigma Around Fibroid Management
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Uterine Fibroid Treatment Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Gonadotropin-releasing Hormone Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Gonadotropin-releasing Hormone Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Gonadotropin-releasing Hormone Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Gonadotropin-releasing Hormone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Gonadotropin-releasing Hormone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Gonadotropin-releasing Hormone Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Non-hormonal Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Non-hormonal Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Non-hormonal Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Subserosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Subserosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Subserosal Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 32: World Recent Past, Current & Future Analysis for Intramural Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 33: World Historic Review for Intramural Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: World 15-Year Perspective for Intramural Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 35: World Recent Past, Current & Future Analysis for Submucosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 36: World Historic Review for Submucosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: World 15-Year Perspective for Submucosal Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 38: World Recent Past, Current & Future Analysis for Pedunculated Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 39: World Historic Review for Pedunculated Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: World 15-Year Perspective for Pedunculated Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 41: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: USA Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 44: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: USA Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 47: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: USA Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
CANADA
- TABLE 50: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: Canada Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 53: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Canada Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 56: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Canada Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
JAPAN
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 59: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Japan Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 62: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: Japan Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 65: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Japan Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
CHINA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 68: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: China Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 71: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: China Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 74: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: China Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
EUROPE
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 77: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 78: Europe Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 80: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Europe Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 83: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Europe Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 86: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Europe Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
FRANCE
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 89: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: France Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 92: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: France Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 95: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: France Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
GERMANY
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 98: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Germany Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 101: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Germany Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 104: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Germany Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
ITALY
- TABLE 107: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Italy Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 110: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Italy Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 113: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Italy Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
UNITED KINGDOM
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 116: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: UK Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 119: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: UK Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 122: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: UK Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
SPAIN
- TABLE 125: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: Spain Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 128: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: Spain Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 131: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Spain Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
RUSSIA
- TABLE 134: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Russia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 137: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 138: Russia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 140: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Russia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
REST OF EUROPE
- TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
ASIA-PACIFIC
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 153: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
AUSTRALIA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 164: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Australia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 167: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Australia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 170: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 171: Australia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
INDIA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 173: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: India Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 176: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: India Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 179: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: India Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
SOUTH KOREA
- TABLE 182: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: South Korea Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 185: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: South Korea Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 188: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: South Korea Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
- TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
LATIN AMERICA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 200: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 201: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 203: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 206: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Latin America Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 208: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 209: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 211: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
ARGENTINA
- TABLE 212: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 213: Argentina Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 214: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 215: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 216: Argentina Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 217: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 218: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 219: Argentina Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 220: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
BRAZIL
- TABLE 221: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 222: Brazil Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 223: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 224: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 225: Brazil Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 226: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 227: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 228: Brazil Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 229: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
MEXICO
- TABLE 230: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 231: Mexico Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 232: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 233: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 234: Mexico Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 235: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 236: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 237: Mexico Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 238: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
- TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 240: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 241: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 243: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 244: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 246: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 247: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
MIDDLE EAST
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 248: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 249: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 250: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 251: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 252: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 253: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 254: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 255: Middle East Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 256: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 257: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 258: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 259: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
IRAN
- TABLE 260: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 261: Iran Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 262: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 263: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 264: Iran Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 265: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 266: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 267: Iran Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 268: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
ISRAEL
- TABLE 269: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 270: Israel Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 271: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 272: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 273: Israel Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 274: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 275: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 276: Israel Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 277: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
SAUDI ARABIA
- TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 279: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 280: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 282: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 283: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 285: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 286: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
- TABLE 287: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 288: UAE Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 289: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 290: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 291: UAE Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 292: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 293: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 294: UAE Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 295: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
- TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 297: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 298: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 300: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 301: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 303: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 304: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
AFRICA
- Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 305: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 306: Africa Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 307: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 308: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 309: Africa Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 310: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
- TABLE 311: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 312: Africa Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 313: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030